2014

European Market For Varicose Vein Treatment Devices Will Reach $65 Million by 2022 Although the Low Cost of Surgical Stripping Will Remain Appealing, There Will Be a Shift Toward Less Invasive Treatments, According to Findings from Decision Resources Group

BURLINGTON, Mass., Feb. 18, 2014  /PRNewswire/ --  Decision Resources Group finds that adoption of treatments for varicose veins in Europe will increase overall but will vary significantly by country, due to the uneven impact of the European economic crisis and the differing preferences of physicians.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36768LOGO )

Procedure volumes for surgical stripping will decline overall through 2022. However, some demand for this relatively invasive procedure will continue, since public healthcare systems in all five countries reimburse for it, thus making it cost-effective for patients. Specialists in Spain will be most likely to continue to perform surgical procedures, due to a lack of training for vascular surgeons on sclerotherapy and endovenous ablation.

Despite the ongoing use of surgical stripping, sclerotherapy volumes will rise for primary and adjunctive varicose vein and spider vein treatments. Growth rates are particularly strong in France and Italy. Liquid sclerotherapy was pioneered by physicians from these countries and the procedure is thus well established. Conversely, concerns regarding occlusion and recurrence rates in sclerotherapy have not only impeded adoption of this procedure in the United Kingdom, but have also resulted in increased restrictions in reimbursement and clinical guidelines, although clinical support is gradually resulting in more favorable guidelines.

"Although reimbursement and cost will influence adoption of all varicose vein procedure types to varying degrees, these factors will have the greatest impact on the endovenous ablation device market," said Decision Resources Group Analyst Leila Bautista. "The price of these devices is relatively high, and there is currently insufficient reimbursement in the public health care system. A large proportion of endovenous ablation procedures must therefore be paid for out-of-pocket, encouraging patients to seek out alternative treatments. However, patients with private insurance will continue to seek endovenous ablation procedures, and procedure volumes will grow moderately."

Decision Resources Group's European Markets for Varicose Vein Treatment Devices 2014 report includes procedure information for phlebectomies as well as unit, procedure, average selling price and revenue information, along with market drivers and limiters and a competitive landscape for endovenous ablation devices, surgical stripping devices and sclerotherapy agents in France, Germany, Italy, Spain and the United Kingdom. Supplemental country coverage is also available for Austria, Belgium, the Czech Republic, Denmark, Finland, Greece, Hungary, the Netherlands, Norway, Poland, Portugal, Romania, Sweden, Switzerland and Ukraine, as well as in aggregate for the rest of the European countries.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

 

Christopher Comfort
Decision Resources Group
781-993-2597
ccomfort@dresources.com


SOURCE Decision Resources



RELATED LINKS
http://www.decisionresourcesgroup.com

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.